Background-Small studies have reported women to have worse outcomes and more adverse events after implantation of mechanical circulatory support device compared with men. To further evaluate sex differences in outcome, we used the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS). Methods and Results-There were 401 women (pulsatile devicesϭ78) and 1535 men (pulsatile devicesϭ402) from 89 institutions who were prospectively enrolled into the INTERMACS database for primary implantation of a left ventricular assist device (LVAD) between June 23, 2006, and March 31, 2010. Extensive preimplantation and outcome data were collected on all patients. With a mean follow-up of 7 months, 67 females (17%) died and 250 males (16%) died. There was no statistically significant sex difference in mortality for either pulsatile-flow (Pϭ0.82) or continuous-flow (Pϭ0.95) devices in adjusted and unadjusted models. There were also no statistically significant sex differences with time to first infection, bleeding, or device malfunction. However, female sex was associated with an increased hazard of first neurological event (adjusted hazard ratio, 1.44; 95% CI, 1.05-1.96; Pϭ0.020). Conclusions-There were no significant sex differences in mortality, time to first infection, bleeding, or device malfunction with either pulsatile-or continuous-flow LVADs. However, women had an increased risk of first neurological event. For urgent/emergent mechanical support, the benefit of LVAD support likely outweighs the risk, but it remains less clear for women undergoing elective LVAD implantation. (Circ Heart Fail. 2012;5:234-240.)
S ex-specific mechanical circulatory support outcome data remain limited. Several studies have suggested an increased mortality and/or higher likelihood of bleeding and neurological events in women compared with men after implantation of mechanical circulatory support devices. [1] [2] [3] [4] [5] [6] However, these studies often had few female participants, focused mainly on use of pulsatile-flow devices, and provided limited information regarding severity of illness before mechanical circulatory support. In a single-center study in which women had a worse prognosis, survival after mechanical circulatory support correlated best with the degree of medical severity before ventricular assist device implantation (and not sex). 6 
Clinical Perspective on p 240
The Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) provides a unique opportunity to evaluate sex differences in outcome and adverse events after implantation of mechanical support. Since the first annual report in 2008, 5 the number of women in the database has increased from 83 to 401 and the number of men has increased from 304 to 1535. There are also sufficient data to compare pulsatile-with continuous-flow devices. Our objective was to determine if there are any sex differences in outcome and adverse events after primary implantation of left ventricular assist devices (LVADs).
Methods

INTERMACS Registry
The INTERMACS is a national registry for patients implanted with a Food and Drug Administration-approved mechanical circulatory support device designed to support patients for long periods. It is an audited registry, and adverse events are reviewed by a Medical Events Committee for reasonableness and internal consistency. Registry participation is mandatory for all Centers for Medicare and Medicaid Services-approved "destination" mechanical circulatory support device implantation centers. The registry was created and has been maintained by the University of Alabama INTERMACS Data Coordinating Center since June 2005, and is supported by the National Heart, Lung, and Blood Institute, the Food and Drug Administration, and the Centers for Medicare and Medicaid Services. Participating centers are required to obtain institutional review board approval before initiating data collection, and data are trans- 
Outcomes and Adverse Events
The primary outcome was all-cause mortality, with data censored at transplantation or device removal after recovery of myocardial function. Secondary outcomes were time to first major bleed, device malfunction, major infection, or neurological dysfunction. These adverse events were prospectively defined and contained in the operations manual. Briefly, suspected internal or external major bleeding was defined as bleeding that resulted in death, reoperation, hospitalization, or blood transfusion. Device malfunction was defined as failure of one of the parts of the mechanical circulatory support device. Major infection was defined clinically with symptoms and/or signs warranting the use of antibiotics for treatment. Neurological dysfunction was defined as a transient ischemic attack or a cerebrovascular accident (hemorrhagic or ischemic). Participating registry centers were required to update the database within 30 days of an event except for device malfunction, which was to be entered within 72 hours of occurrence (http://www.INTERMACS.org).
Statistical Analysis
Sex-specific baseline characteristics were reported for adult patients who underwent primary implantation of an intracorporeal LVAD. Continuous variables were expressed as means, except for skewed variables, which were expressed as medians. Categorical variables were expressed as frequencies. Discrete variables were compared using the 2 test of significance, unless the frequencies were small, in which case a Fisher exact test was used. Median values were compared with a nonparametric test (median 2-sample test). Otherwise, continuous variables were compared using the t test. For variables with Յ12% of data omitted, we used mean value imputation to fill in the missing data. We excluded the following variables that were missing Ͼ12% of data: college education, total cholesterol, prealbumin, cardiac output, cardiac index, right atrial pressure, pulmonary capillary wedge pressure, pulmonary artery pressures, pulmonary vascular resistance, left ventricular ejection fraction Ͻ20%, severe right ventricular dysfunction, and left ventricular end-diastolic diameter. Sex-specific survival analysis was performed for pulsatile-and continuous-flow LVADs using the KaplanMeier method, with censoring for heart transplantation or cardiac recovery. Cox proportional hazard models were created to assess the association between sex and outcome, including mortality, bleeding, infection, device malfunction, and neurological event. Two models were created for each outcome: model 1 adjusted for sex, and model 2 adjusted for sex, age, bilirubin, ascites, INTERMACS level, international normalized ratio, creatinine, platelets, aspartate aminotransferase, hemoglobin, blood urea nitrogen, albumin, inotropes, and type of LVAD support. Variables included in regression models were selected for the known significance based on prior literature. [7] [8] [9] [10] We evaluated the proportional hazards assumption and found no obvious violations. PՅ0.05 was considered statistically significant. All analyses were performed using SAS 8.2 software (SAS Institute; Cary, NC). A competing outcome figure was calculated with an internally written SAS macro that implements the Nelson method for estimating the distribution of cumulative, repeating events. 11
Results
Patient Characteristics
There were 401 women (78 pulsatile devices) and 1535 men (402 pulsatile devices) who underwent primary implantation of an intracorporeal LVAD. Baseline characteristics are shown in Table 1 . Women, compared with men, were younger; had a smaller body surface area (BSA) and a greater history of cancer; exhibited less alcohol abuse and coronary artery bypass graft surgery; and had lower serum blood urea nitrogen, creatinine, hemoglobin, and total bilirubin levels. There were no clinically significant sex differences in the following baseline characteristics: diabetes mellitus, chronic obstructive lung disease, peripheral vascular disease, current tobacco use, implantable cardioverter defibrillators, use of LVAD as a bridge to transplantation, systolic blood pressure, serum sodium, and liver function test results. More women were listed in critical cardiogenic shock, with no sex differences in use of intra-aortic balloon pumps, inotrope dependency, and ventilator support. There were also no sex differences in concurrent surgery during implantation of LVAD.
Outcomes
With a mean follow-up of 7 months, 67 (17%) of the females died (25 with pulsatile-flow devices) and 250 (16%) of the males died (107 with pulsatile-flow devices). The cause of death was similar among groups, except for a higher percentage of cardiovascular deaths and a lower percentage of neurological deaths among men compared with women for both pulsatile-and continuous-flow devices (Table 2) . There were 622 patients who underwent heart transplantation (95 women and 527 men). Few patients recovered and had the LVAD removed (Ͻ2%). The 
RV failure 8 (7) 1 (4) 6 (4) 5 (12) Sudden death 2 (2)
3 (12) 12 (8) 6 (14) Fluid/electrolyte disorder
Hemorrhage 10 (9) 1 (4) 12 (8) 3 (7) Hematologic 1-year survival after primary LVAD implantation was 70% for women and 72% for men with pulsatile-flow devices and 83% for women and men with continuous-flow devices. There was no statistically significant sex difference in allcause mortality for pulsatile-or continuous-flow devices in both unadjusted ( Figure 1A and 1B) and adjusted analyses (Table 3) . However, survival was better for continuous-flow devices compared with pulsatile-flow devices for both women and men. Competing outcome data for pulsatile-flow intracorporeal LVADs (Figure 2A and 2B) were notable for women and men with similar 6-month survival. However, men with a pulsatile-flow LVAD underwent heart transplantation more frequently than women. For continuous-flow intracorporeal LVADs, women and men had similar competing outcome data, as shown in Figure 3A and 3B.
Adverse Events
Adverse events were more common in pulsatile-flow LVADs than in continuous-flow LVADs (Figure 4 ). There were no statistically significant sex differences in time to first infection, bleeding, or device malfunction with use of continuous-or pulsatile-flow LVADs ( Figure 4A , 4B, and 4D), even after multivariate analyses (Table 3) . However, women, compared with men, had a shorter time to first neurological event with pulsatile-flow LVADs and a trend toward shorter time to first neurological event with continuous-flow LVADs ( Figure 4C ). Multivariate analysis adjusting for many risk factors, including type of device, prior cerebrovascular accident/transient ischemic attack, carotid disease, and BSA, revealed female sex to be associated with an increased hazard of neurological events (Table 3 ). There was no interaction between sex and device type for any of the adverse events, suggesting that the sex differences in neurological event after multivariate analysis were not dependent on type of LVAD implanted.
Discussion
There was no significant sex difference in mortality with either a pulsatile-or a continuous-flow LVAD for the 1936 patients (21% female) in the INTERMACS registry and no significant sex differences in time to first bleed, infection, or device malfunction. However, women, compared with men, had a shorter time to first neurological event that was statistically significant in unadjusted and adjusted models. Women and men with continuous-flow LVADs had similar competing outcomes, but women compared with men with pulsatile-flow LVADs were less likely to undergo heart transplantation. Few patients recovered left ventricular systolic function after VAD implantation, and survival was best for both women and men after implantation of continuousflow LVADs compared with pulsatile-flow devices. Our findings regarding the benefits and risks of LVADs in women and men form the largest published analysis to date assessing sex differences. The lack of sex differences in allcause mortality after LVAD implantation is reassuring, and the excellent survival rate for continuous-flow devices is similar to those of recently published studies. 12, 13 One-year survival after implantation of continuous-flow LVADs was 83%, which is better than smaller studies [12] [13] [14] [15] and comparable to the 1-year expected survival after heart transplantation in the United States, 16 making it reasonable as a bridge to transplantation for patients with heart failure in whom medical therapy has failed. Adverse events were similar between women and men, except for first neurological events, which were more likely in women, even after adjusting for type of LVAD, history of carotid disease, cerebrovascular accident/transient ischemic attack, BSA, and age. A higher rate of neurological events in women has been previously reported in smaller studies for the HeartMate II. 2, 12 In preliminary studies with the HeartMate II continuous-flow devices, patients (nϭ10) with a smaller BSA (1.2-1.5 m 2 ) had a higher incidence of neurological events than patients (nϭ126) with larger BSAs. The cohort with a smaller BSA was all women, raising concern that the finding may be related to sex because, in the aggregate HeartMate II study with 194 patients, there were more neurological events in women (nϭ44) compared with men (nϭ150). 2 With Ͼ1900 patients in the INTERMACS registry, including 401 women, the higher risk for first neurological event in women after LVAD implantation remains a concern, even after adjusting for many variables, including type of LVAD and BSA. The cause for sex differences remains unknown. Information regarding international normalized ratio, von Willebrand factor, and anticoagulation therapy at the time of neurological event was not available in our registry, but in a retrospective HeartMate II LVAD analysis that showed women to be at higher risk for stroke, there was no sex difference in mean serum international normalized ratio, partial thromboplastin time, platelet count, or average systolic blood pressure at the time of neurological event. 12 Further research is necessary to determine whether sex differences in neurological events are due to sex differences in the pharmacokinetics and pharmacodynamics of antiplatelet and anticoagulation therapy or sex differences in thrombotic risk after implantation of an LVAD. Given the higher risk of thromboembolism in women with atrial fibrillation compared with men 17 and the sex differences in the pharmacokinetics and pharmacodynamics of many cardiovascular drugs, 18 -21 both hypotheses are plausible.
Overall, there was better survival and fewer adverse events for patients with primary implantation of continuous-flow devices compared with pulsatile-flow devices. This is important, especially for women, in light of Food and Drug Administration criticism that the HeartMate II was approved with preliminary data showing a higher rate of stroke in women compared with men and a trend to a higher rate of infection and bleeding. 22 Although women have a higher risk of first neurological events after LVAD implantation, there were fewer adverse events and better survival with continuous-flow devices compared with pulsatile-flow devices.
Competing outcomes were similar for women and men who underwent implantation of continuous-flow LVAD. However, women who had pulsatile-flow devices were less likely than men to undergo heart transplantation, despite a similar preimplantation device strategy (listed for bridge to transplantation: 43% male and 48% female). The reason for this remains unclear. The INTERMACS registry did not track cause for inactivation (United Network for Organ Sharing status 7), date of reactivation, or important determinants of transplantation, such as degree of sensitization (ie, high panel of reactive antibodies). Given the higher percentage of male heart donors in the United States, 16 sex differences in rate of heart transplantation may simply reflect the higher likelihood that a male donor heart would be best suited, based on size, to fit in a male heart failure recipient and the lower likelihood that a male recipient would be sensitized.
Limitations of this study include the inability of our registry to confirm death/heart transplantation with external sources, such as the Social Security Death Index and the United Network for Organ Sharing database, because patient identification was not collected to maintain patient confidentiality. Compliance with data entry was excellent. However, certain data, such as central hemodynamics, total cholesterol, estimates of severe right ventricular dysfunction, and left ventricular end-diastolic diameter, were missing in Ͼ40% of the patients and, therefore, not used in this study. Other information not obtained included data regarding inactivation on the heart transplant wait list, date of reactivation, amount of anticoagulation/antiplatelet therapy, quantification of "reactive antibodies," and von Willebrand factor-dependent ristocetin-induced platelet aggregation, which may, in the future, be collected and help us better understand other sex differences. Our data were also limited to 89 centers, which is not all inconclusive but does represent most US cardiac surgical centers implanting mechanical circulatory support. Registries are also subject to human error with respect to data entry and quality control; however, INTERMACS had an operational auditing program.
Conclusion
In summary, there were no significant sex differences in mortality with either a pulsatile-or a continuous-flow device, but women had a shorter time to first neurological event in both unadjusted and adjusted analyses. Further research is needed to better understand the mechanisms underlying these sex differences.
